581 692
prostatic hyperplasia: a 1-year, open-label extension study. BJU Int
2011;107:1110–6
.
[60] Oelke M, Bachmann A, Descazeaud A, et al. Guidelines on the
management of male lower urinary tract symptoms (LUTS), incl.
benign prostatic obstruction (BPO). Arnhem: European Association
of Urology.
https://uroweb.org/wp-content/uploads/12_Male_ LUTS_LR-May-9th-2012.pdf .[61]
Novara G, Tubaro A, Sanseverino R, et al. Systematic review and meta-analysis of randomized controlled trials evaluating silodosin in the treatment of non-neurogenic male lower urinary tract symptoms suggestive of benign prostatic enlargement. World J Urol 2013;31:997–1008.[62]
Martinez-Salamanca JI, Carballido J, Eardley I, et al. Phosphodies- terase type 5 inhibitors in the management of non-neurogenic male lower urinary tract symptoms: critical analysis of current evidence. Eur Urol 2011;60:527–35.[63]
Gacci M, Corona G, Salvi M, et al. A systematic review and meta- analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2012;61:994–1003.E U R O P E A N U R O L O G Y 7 1 ( 2 0 1 7 ) 5 7 0 – 5 8 1
581